Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mersana Therapeutics Inc.

0.5443
+0.01913.64%
Volume:1.91M
Turnover:1.02M
Market Cap:67.84M
PE:-0.96
High:0.5547
Open:0.5195
Low:0.5110
Close:0.5252
Loading ...

Company Profile

Company Name:
Mersana Therapeutics Inc.
Exchange:
NASDAQ
Establishment Date:
2001
Employees:
102
Office Location:
840 Memorial Drive,Cambridge,Massachusetts,United States
Zip Code:
02139
Fax:
- -
Introduction:
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Directors

Name
Position
Anna Protopapas
President, Chief Executive Officer and Director
David Mott
Chairman
Andrew A. F. Hack
Director
Elaine V. Jones
Director
Kristen Hege
Director
Sara Nayeem
Director

Shareholders

Name
Position
Anna Protopapas
President, Chief Executive Officer and Director
Michael Kaufman
Senior Vice President of Chemistry, Manufacturing and Controls
Donald A. Bergstrom
Chief Medical Officer
Eva M. Jack
Chief Business Officer
Timothy B. Lowinger
Chief Scientific Officer